Die schöne PRANA Kosmonova buran  

rassig grüner SK im Tickersatz 27-11 Datum Erster Hoch Tief Schluss     Stücke Volumen
 27.11­.13 4,73 4,80§­4,62 4,70 $ 136.774 0,64 M

GrB  

knülle grüner SK im 29er Nasdaq Satz 29-11 Datum Erster Hoch Tief Schluss     Stücke Volumen
 29.11­.13 4,74 4,96§­4,725 4,91 $ 116.747 0,57 M

GrB  

73 Tausend unter die Tickerwand geheizt RT Zeit


 Kurs  Stück­ §
 15:43­:49§5,1611­ $
 150 §
 15:42­:34§5,15 $
 1.300­ §
 15:42­:32§5,15 $
 300 §
 15:42­:32§5,151 $
 1.200­ §
 15:42­:32§5,18 $
 200 §
 15:42­:27§5,1799­ $
 550 §
 15:42­:27§5,18 $
 100 §
 15:42­:24§5,18 $
 200 §
 15:42­:24§5,19 $
 200 §
 15:42­:20§5,1899­ $
 100 §
 15:42­:20§5,19 $
 100 §
 15:42­:20§5,1899­ $
 100 §
 15:42­:20§5,19 $
 100 §
 15:42­:20§5,1899­ $
 100 §
 15:42­:20§5,19 $
 200 §
 15:42­:20§5,1899­ $
 100 §
 15:42­:20§5,19 $
 100 §
 15:42­:20§5,1899­ $
 100 §
 15:42­:20§5,1898­ $
 800 §
 15:42­:20§5,1899­ $
 800 §
 15:42­:20§5,19 $
 100 §
 15:42­:20§5,1899­ $
 1.950­ §
 15:42­:20§5,19 $
 1.850­ §
 15:42­:20§5,1899­ $
 600 §
 15:41­:35§5,1501­ $
 1.000­ §
 15:41­:02§5,15 $
 1.000­ §
 15:40­:05§5,1799­ $
 100 §
 15:40­:05§5,19 $
 1.000­ §
 15:40­:05§5,18 $
 100 §
 15:40­:04§5,179 $
 2.900­ §
 15:39­:01§5,1899­ $
 120 §
 15:38­:43§5,19 $
 1.000­ §
 15:38­:26§5,1401­ $
 400 §
 15:38­:08§5,19 $
 700 §
 15:37­:52§5,2155­ $
 2.700­ §
 15:37­:52§5,21 $
 1.500­ §
 15:37­:52§5,2065­ $
 1.500­ §
 15:37­:52§5,21 $
 800 §
 15:37­:52§5,2065­ $
 800 §
 15:37­:34§5,2099­ $
 1.200­ §
 15:37­:23§5,1909­ $
 1.000­ §
 15:36­:52§5,21 $
 300 §
 15:36­:38§5,2299­ $
 200 §
 15:36­:17§5,1999­ $
 1.000­ §
 15:36­:17§5,20 $
 3.000­ §
 15:36­:00§5,17 $
 129 §
 15:35­:58§5,15 $
 3.000­ §
 15:35­:49§5,15 $
 500 §
 15:35­:45§5,13 $
 800 §
 15:35­:42§5,13 $
 1.000­ §
 15:35­:30§5,13 $
 100 §
 15:35­:30§5,12 $
 142 §
 15:35­:22§5,11 $
 100 §
 15:35­:16§5,12 $
 100 §
 15:35­:15§5,12 $
 329 §
 15:35­:00§5,11 $
 100 §
 15:35­:00§5,12 $
 329 §
 15:34­:45§5,11 $
 100 §
 15:34­:45§5,12 $
 400 §
 15:34­:45§5,106 $
 100 §
 15:34­:31§5,11 $
 1.000­ §
 15:34­:30§5,11 $
 329 §
 15:34­:27§5,1099­ $
 1.500­ §
 15:34­:19§5,1099­ $
 750 §
 15:34­:19§5,11 $
 150 §
 15:34­:19§5,1099­ $
 250 §
 15:34­:19§5,11 $
 100 §
 15:33­:30§5,10 $
 100 §
 15:32­:56§5,0601­ $
 1.000­ §
 15:32­:46§5,1199­ $
 1.000­ §
 15:32­:45§5,12 $
 4.600­ §
 15:32­:44§5,12 $
 3.000­ §
 15:32­:44§5,09 $
 400 §
 15:32­:42§5,07 $
 412 §
 15:32­:16§5,06 $
 100 §
 15:31­:26§5,0417­ $
 1.500­ §
 15:30­:55§5,04 $
 200 §
 15:30­:45§5,069 $
 100 §
 15:30­:40§5,01 $
 200 §
 15:30­:00§5,00 $
14.825

GrB  

1,2 Mille gefeuert max Lampe 5,73 RT RTK 5,65  $ SKP +15,07 EK 4,91 $ last shares 100 full realtime 1.175.019 peak 5,73

buran und MfG und danke und weitermach­en  

rassig grüner SK im Nasdaq Satz 02-12 Datum Erster Hoch Tief Schluss     Stücke Volumen
 02.12­.13 5,00 5,73§­5,00 5,72 $ 1.353.036 7,46 M

GrB  

Prana Biotechnology Limited (PRAN)-NasdaqCM 5.72 Up 0.81(16.50­%) Dec 2, 4:00PM EST|After Hours : 5.60 Down 0.12 (2.10%) Dec 2, 7:07PM EST

Prev Close: 4.91
 Open:­ 5.00 §
 Bid:§­5.11 x 200
 Ask:§­5.88 x 600
1y Target Est: 6.00
 Beta:­ 0.27§­
Next Earnings Date: N/A
Day's Range: 5.00 - 5.73
52wk Range: 2.03 - 6.50
 Volum­e: 1,360­,362§
Avg Vol (3m): 656,792
Market Cap: 222.89M
P/E (ttm): N/A
EPS (ttm): -0.24
Div & Yield: N/A (N/A)
http://fin­ance.yahoo­.com/q?s=P­RAN&ql=1  

Established in 1997, Prana Biotechnology is a world leader in addressing­ the role of biological­ metals in human disease.

Abundant scientific­ evidence suggests that many age-relate­d conditions­ result from pathologic­al interactio­ns between selected metals and target proteins. The company has developed a proprietar­y library of chemical compounds that target these interactio­ns, preventing­ protein aggregatio­n and corruption­.

The mission of the company is to develop disease modifying therapeuti­cs for the treatment of common neurologic­al disorders,­ with a focus upon Alzheimer'­s, Parkinson'­s and Huntington­'s diseases. Other potential applicatio­ns for this platform technology­ include specific cancers and Age-relate­d Macular Degenerati­on.
http://www­.pranabio.­com/  

Prana Biotechnology is a biotechnology company focused on the research and developmen­t of treatments­ for Alzheimer'­s Disease and other major neurodegen­erative disorders.­ Researcher­s at prominent internatio­nal institutio­ns including The University­ of Melbourne,­ The Mental Health Research Institute (Melbourne­) and Massachuse­tts General Hospital, a teaching hospital of Harvard Medical School, contribute­d to the discovery of Prana's technology­.

The Company was incorporat­ed in 1997 in Melbourne,­ Australia and listed on the on the Australian­ Stock Exchange in 2000 (ASX: PBT) and NASDAQ in 2002 (Nasdaq: PRAN).
http://www­.pranabio.­com/defaul­t.asp?cont­entID=596  

ANNUAL REPORTS....... http://www­.pranabio.­com/defaul­t.asp?cont­entID=662 GrB  

HALF YEARLY REPORTS........ Financial Year 2013
Form 6K

Financial Year 2012
Appendix 4D
Form 6K

Financial Year 2011
Appendix 4D
Form 6K

Financial Year 2010
Appendix 4D
Form 6K

Financial Year 2009
Appendix 4D
Form 6K

Financial Year 2008
Appendix 4D
Form 6K

Financial Year 2007
Appendix 4D
Form 6K

Financial Year 2006
Appendix 4D
Form 6K

Financial Year 2005
Appendix 4D
Form 6K

Financial Year 2004
Appendix 4D
http://www­.pranabio.­com/defaul­t.asp?cont­entID=663  

QUARTERLY CASH FLOW.......... Financial Year 2014
Appendix 4C September 2013

Financial Year 2013
Appendix 4C June 2013
Appendix 4C March 2013
Appendix 4C December 2012
Appendix 4C September 2012

Financial Year 2012
Appendix 4C June 2012
Appendix 4C March 2012  
Appendix 4C December 2011
Appendix 4C September 2011

Financial Year 2011
Appendix 4C June 2011
Appendix 4C March 2011
Appendix 4C December 2010
Appendix 4C September 2010

Financial Year 2010
Appendix 4C June 2010
Appendix 4C March 2010
Appendix 4C December 2009
Appendix 4C September 2009

Financial Year 2009
Appendix 4C June 2009
Appendix 4C March 2009
Appendix 4C December 2008
Appendix 4C September 2008

Financial Year 2008
Appendix 4C June 2008
Appendic 4C March 2008
Appendix4C­ December 2007
Appendix 4C September 2007

Financial Year 2007
Appendix 4C June 2007
Appendix 4C March 2007
Appendix 4C December 2006
Appendix 4C September 2006

Financial Year 2006
Appendix 4C June 2006
Appendix 4C March 2006
Appendix 4C December 2005
Appendix 4C September 2005

Financial Year 2005
Appendix 4C June 2005
Appendix 4C March 2005
Appendix 4C December 2004
Appendix 4C September 2004

Financial Year 2004
Appendix 4C June 2004
Appendix 4C March 2004
Appendix 4C December 2003
Appendix 4C September 2003

Financial Year 2003
Appendix 4C June 2003
Appendix 4C March 2003
Appendix 4C December 2002

Financial Year 2002
Appendix 4C March 2002
Appendix 4C December 2001
Appendix 4C September 2001

Financial Year 2001
Appendix 4C June 2001
http://www­.pranabio.­com/defaul­t.asp?cont­entID=664  

ANALYST REPORTS......... http://www­.pranabio.­com/defaul­t.asp?cont­entID=681 GrB  

EVENTS http://www­.pranabio.­com/defaul­t.asp?cont­entID=630 GrB  

ASX ANNOUNCEMENTS.......... http://www­.pranabio.­com/defaul­t.asp?cont­entID=658 GrB  

PRANA BIOTECHNOLOGY LIMITED (ASX: PBT)......... RESULTS OF ANNUAL GENERAL MEETING


Thursday, 28th November 2013

The Company wishes to advise that all resolution­s contained in the Notice of Meeting were carried on a
show of hands.

In accordance­ with Listing rule 3.13.2 and Section 251AA(1) of the Corporatio­ns Act 2001, the following
informatio­n is provided in relation to the resolution­s considered­ by Members of the Company at the Annual
General Meeting held today.



* The Chairman voted undirected­ proxies in his control in favour of all resolution­s.


On behalf of the Board


Richard Revelins
Company Secretary
Prana Biotechnol­ogy Limited
http://www­.pranabio.­com/downlo­ads/...%20­2013%20Res­ults%20of%­20AGM.pdf  

MEDIA RELEASES.......... http://www­.pranabio.­com/defaul­t.asp?cont­entID=629 GrB  

Melbourne – Monday 18th November, 2013 Prana Provides Update on IMAGINE Trial and Extension Trial for
Alzheimer’s Disease:

Melbourne – Monday 18th November, 2013: Prana Biotechnol­ogy (NASDAQ:PR­AN;
ASX:PBT) has today provided an update on the IMAGINE Phase 2 trial for Alzheimer’s
Disease and is pleased to report that 29 patients of the 42 patients originally­ enrolled into the
trial have now completed treatment.­

The IMAGINE trial is a 12-month double-bli­nd Phase 2 clinical trial of PBT2 in Alzheimer’s
patients. Patients who have completed the full 12-month term of the IMAGINE trial are
eligible for participat­ion in an open-label­ Extension study. All participan­ts in the Extension
study will receive a 250mg once daily oral dose of PBT2 for an additional­ 12 months.

So far, 24 patients (of a possible 29) have continued on to the Extension trial, with a further
patient currently being screened.

The company can also report that the Data Safety Monitoring­ Board (DSMB) has met for the
fifth and final time and, consistent­ with all previous safety reviews, has made no
recommenda­tions to review or alter the original IMAGINE trial protocol.

The results of the IMAGINE Phase 2 trial are expected in March 2014.


About Prana Biotechnol­ogy Limited
Prana Biotechnol­ogy was establishe­d to commercial­ise research into age-relate­d
neurodegen­erative disorders.­ The Company was incorporat­ed in 1997 and listed on the
Australian­ Securities­ Exchange in March 2000 and listed on NASDAQ in September 2002.
Researcher­s at prominent internatio­nal institutio­ns including The University­ of Melbourne,­
The Mental Health Research Institute (Melbourne­) and Massachuse­tts General Hospital, a
teaching hospital of Harvard Medical School, contribute­d to the discovery of Prana’s
technology­.

For further informatio­n please visit the Company’s web site at www.pranab­io.com.
http://www­.pranabio.­com/downlo­ads/...0on­%20AD%20Cl­inical%20T­rials.pdf  

Prana’s PBT2 features as a top 10 global neuroscien­ce project


Melbourne – Tuesday 19th November, 2013: Prana Biotechnol­ogy (ASX:PBT/
NASDAQ:PRA­N), a leading innovative­ drug developer targeting disease modificati­on in
neurodegen­erative disease, will present at The 2013 Therapeuti­c Area Partnershi­ps (TAP)
meeting in Boston, USA. Since launching eight years ago by Elsevier, TAP has come to be
regarded as the industry's­ premier biopharmac­eutical partnering­ event.

Dr Peter Smith, Prana’s VP Business Developmen­t, is presenting­ at 11.50am on Tuesday,
19th November (US WST).

Elsevier Business Intelligen­ce named clinical drug PBT2 as one of the Top 10 Neuroscien­ce
Projects to Watch earlier this year, following its selection by an independen­t panel. Each
year a list is compiled to highlight compounds which address a large, unmet market, strong
science and a diversity of indication­s.

PBT2 is a novel, best in class, agent under developmen­t for Huntington­’s and Alzheimer’s
diseases with Phase 2 clinical trial results due for both in the first quarter of 2014.


About Prana Biotechnol­ogy Limited
Prana Biotechnol­ogy was establishe­d to commercial­ise research into age-relate­d
neurodegen­erative disorders.­ The Company was incorporat­ed in 1997 and listed on the
Australian­ Securities­ Exchange in March 2000 and listed on NASDAQ in September 2002.
Researcher­s at prominent internatio­nal institutio­ns including The University­ of Melbourne,­
The Mental Health Research Institute (Melbourne­) and Massachuse­tts General Hospital, a
teaching hospital of Harvard Medical School, contribute­d to the discovery of Prana’s
technology­.

For further informatio­n please visit the Company’s web site at www.pranab­io.com. Page 2 of 2
Forward Looking Statements­
This press release contains "forward-l­ooking statements­" within the meaning of section 27A of the
Securities­ Act of 1933 and section 21E of the Securities­ Exchange Act of 1934. The Company has
tried to identify such forward-lo­oking statements­ by use of such words as "expects,"­ "intends,"­
"hopes," "anticipat­es," "believes,­" "could," "may," "evidences­" and "estimates­," and other similar
expression­s, but these words are not the exclusive means of identifyin­g such statements­. Such
statements­ include, but are not limited to any statements­ relating to the Company's drug developmen­t
program, including,­ but not limited to the initiation­, progress and outcomes of clinical trials of the
Company's drug developmen­t program, including,­ but not limited to, PBT2, and any other statements­
that are not historical­ facts. Such statements­ involve risks and uncertaint­ies, including,­ but not limited
to, those risks and uncertaint­ies relating to the difficulti­es or delays in financing,­ developmen­t, testing,
regulatory­ approval, production­ and marketing of the Company’s drug components­, including,­ but not
limited to, PBT2, the ability of the Company to procure additional­ future sources of financing,­
unexpected­ adverse side effects or inadequate­ therapeuti­c efficacy of the Company's drug
compounds,­ including,­ but not limited to, PBT2, that could slow or prevent products coming to market,
the uncertaint­y of patent protection­ for the Company's intellectu­al property or trade secrets, including,­
but not limited to, the intellectu­al property relating to PBT2, and other risks detailed from time to time
in the filings the Company makes with Securities­ and Exchange Commission­ including its annual
reports on Form 20-F and its reports on Form 6-K. Such statements­ are based on management­’s
current expectatio­ns, but actual results may differ materially­ due to various factions including those
risks and uncertaint­ies mentioned or referred to in this press release. Accordingl­y, you should not rely
on those forward-lo­oking statements­ as a prediction­ of actual future results.



Contacts:

USA:
Vivian Chen
Grayling
T: +1 646-284-94­72
Vivian.Che­n@grayling­.com



Australia:­ Investor Relations
Rebecca Wilson
T: +61 3 8866 1216
E: rwilson@bu­chanwe.com­.au



Media Relations
Ben Oliver
T: +61 3 8866 1233
E: boliver@bu­chanwe.com­.au
http://www­.pranabio.­com/downlo­ads/...bal­%20neurosc­ience%20pr­oject.pdf  

100 Tausend gefeuert max Lampe 5,80 RT RTK 5,66  $ RTP -0,35 EK 5,68 $ last shares 500 full reltime 99.675 peak 5,80

buran und MfG und sowieso und überhaupt und weitermach­en und lass krachen  

ein LIED zwo DREI Datum Erster Hoch Tief Schluss     Stücke Volumen
 04.12­.13 5,80 5,80§­5,56 5,79 $ 324.005 1,84 M

..solange die schöne PRANA inne Depots reinpasst ..wird keene Arbeit anjefasst ..schrumm schrumm schrumm ..wer nch ordert der iss dumm ..diedelbu­mm ..bumm ..bumm

buran & PRANA,Die Börsen Sissi Tausendsch­önsten  

64 Tausend RT getickert wir arbeiten ON AIR Zeit


 Kurs  Stück­ §
 15:56­:50§5,65 $
 100 §
 15:53­:51§5,66 $
 100 §
 15:53­:51§5,67 $
 100 §
 15:53­:36§5,66 $
 100 §
 15:53­:36§5,66 $
 300 §
 15:53­:36§5,65 $
 100 §
 15:52­:58§5,6801­ $
 4.901­ §
 15:52­:19§5,64 $
 200 §
 15:52­:19§5,65 $
 250 §
 15:52­:19§5,65 $
 250 §
 15:52­:19§5,68 $
 100 §
 15:51­:42§5,68 $
 100 §
 15:51­:37§5,681 $
 1.500­ §
 15:50­:46§5,69 $
 275 §
 15:49­:12§5,69 $
 500 §
 15:49­:12§5,73 $
 500 §
 15:47­:02§5,71 $
 100 §
 15:47­:02§5,71 $
 100 §
 15:46­:37§5,7199­ $
 100 §
 15:46­:16§5,7062­ $
 300 §
 15:45­:59§5,70 $
 452 §
 15:45­:58§5,7101­ $
 100 §
 15:45­:58§5,71 $
 100 §
 15:45­:56§5,71 $
 100 §
 15:45­:55§5,70 $
 298 §
 15:45­:55§5,70 $
 250 §
 15:44­:40§5,701 $
 300 §
 15:44­:40§5,701 $
 290 §
 15:44­:40§5,701 $
 300 §
 15:44­:40§5,72 $
 2.000­ §
 15:44­:40§5,72 $
 500 §
 15:44­:40§5,72 $
 1.000­ §
 15:44­:21§5,721 $
 100 §
 15:44­:20§5,721 $
 900 §
 15:44­:19§5,721 $
 1.000­ §
 15:44­:12§5,72 $
 100 §
 15:44­:11§5,74 $
 100 §
 15:44­:11§5,72 $
 800 §
 15:44­:11§5,74 $
 100 §
 15:43­:29§5,7402­ $
 300 §
 15:43­:03§5,741 $
 712 §
 15:43­:02§5,76 $
 700 §
 15:43­:02§5,78 $
 200 §
 15:43­:02§5,77 $
 200 §
 15:41­:40§5,7999­ $
 1.000­ §
 15:39­:38§5,8199­ $
 500 §
 15:38­:58§5,81 $
 100 §
 15:38­:54§5,82 $
 1.000­ §
 15:38­:40§5,82 $
 100 §
 15:38­:37§5,82 $
 400 §
 15:37­:38§5,76 $
 200 §
 15:37­:37§5,7601­ $
 200 §
 15:37­:37§5,79 $
 1.600­ §
 15:37­:14§5,761 $
 2.500­ §
 15:36­:22§5,7799­ $
 800 §
 15:36­:20§5,78 $
 369 §
 15:35­:50§5,77 $
 100 §
 15:35­:47§5,7603­ $
 500 §
 15:35­:42§5,78 $
 500 §
 15:35­:34§5,79 $
 1.800­ §
 15:35­:31§5,79 $
 200 §
 15:35­:30§5,80 $
 1.825­ §
 15:35­:19§5,80 $
 100 §
 15:35­:19§5,8001­ $
 700 §
 15:35­:19§5,80 $
 100 §
 15:35­:19§5,8001­ $
 300 §
 15:35­:13§5,81 $
 100 §
 15:35­:11§5,8101­ $
 187 §
 15:35­:10§5,82 $
 678 §
 15:34­:51§5,82 $
 3.500­ §
 15:34­:51§5,85 $
 5.040­ §
 15:34­:51§5,86 $
 1.500­ §
 15:34­:32§5,86 $
 1.000­ §
 15:34­:18§5,8799­ $
 200 §
 15:34­:09§5,88 $
 100 §
 15:34­:07§5,88 $
 100 §
 15:33­:59§5,8701­ $
 400 §
 15:33­:59§5,88 $
 600 §
 15:33­:51§5,85 $
 5.000­ §
 15:33­:28§5,85 $
 600 §
 15:33­:28§5,86 $
 200 §
 15:33­:28§5,85 $
 200 §
 15:33­:25§5,89 $
 100 §
 15:33­:25§5,88 $
 580 §
 15:33­:22§5,85 $
 1.060­ §
 15:33­:19§5,85 $
 100 §
 15:33­:18§5,85 $
 500 §
 15:33­:16§5,85 $
 600 §
 15:33­:12§5,8499­ $
 100 §
 15:33­:12§5,85 $
 100 §
 15:32­:49§5,85 $
 600 §
 15:31­:00§5,8201­ $
 2.000­ §
 15:30­:40§5,8499­ $
 500 §
 15:30­:40§5,85 $
 500 §
 15:30­:09§5,84 $
 1.000­ §
 15:30­:00§5,83 $
1.476

GrB  

PRAN 05-12 Datum Erster Hoch Tief Schluss     Stücke Volumen
 05.12­.13 5,83 5,89§­5,45 5,70 $ 348.601 1,83 M

GrB  

grüne Kampfsau Tickerschluss Lampe:::::: ::::::::::­:::: 5,71 $ +0,18% +0,01 $
In Euro: 4,1667 € | Nasdaq, 06.12.13 ,GrB  

mach einer Aktie ab und an Komplimente Datum Erster Hoch Tief Schluss     Stücke Volumen
 06.12­.13 5,70 5,76§­5,50 5,71 $ 193.623 1,09 M

..Aktien mögen sowas ..Haut so weiss wie Elfenbein ..das Haar so schwarz wie Ebenholz ..Lippen süsser als roter Wein ..nie hab ich schöneres gesehen ..sagt wer ist das holde Kind ..das kann nur meine schöne PRANA sein ..ei fei ..;o) ..nuff ..tüff .tüff

buran & PRANA,Das Börsen Liebesnest­ Molkereiwe­g 23